Molecular mechanisms of biliary excretion of cefditoren and the effects of cefditoren on the expression levels of hepatic transporters

Drug Metabolism and Pharmacokinetics

Volumn 25, Issue 4, 2010, Pages 320-327

  Meng, Qiang ^a   Liu, Qi ^a   Wang, Changyuan ^a   Sun, Huijun ^a   Kaku, Taiichi ^b   Kato, Yukio ^c   Liu, Kexin ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

^b Japan Bioproducts Industry Co Ltd   (Japan)

^c KANAZAWA UNIVERSITY   (Japan)

Author keywords

Bcrp; Biliary excretion; Cefditoren; MRNA expressionreferences; Mrp2

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CEFDITOREN; GLYCOPROTEIN P; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 2; NOVOBIOCIN; ORGANIC ANION TRANSPORTER 2; ORGANIC CATION TRANSPORTER 1; PROBENECID; VERAPAMIL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BILIARY EXCRETION; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG BILE LEVEL; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EXCRETION; DRUG STRUCTURE; GENE EXPRESSION REGULATION; LIVER PERFUSION; MALE; NONHUMAN; PROTEIN FUNCTION; PROTEIN SYNTHESIS INHIBITION; PROTEIN VARIANT; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING;

EID: 77956964015     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.DMPK-09-RG-092     Document Type: Article

References (33)

1. Johnson, D. M., Biedenbachm, D. J., Beach, M. L., Pfaller, M. A. and Jones, R. N.: Antimicrobial activity and in vitro susceptibility test development for cefditoren against Haemophilus influen-zae, Moraxella catarrhalis, and Streptococcus species. Diagn. Microbiol. Infect Dis., 37: 99-105 (2000).
2. Wellington, K. and Curran, M. P.: Cefditoren pivoxil: A review of its use in the treatment of bacterial infections. Drugs., 64: 2597-2618 (2004).
3. Shimada, K.: Significant role of new oral cephem antibiotics.: Focused on cefditoren pivoxil: discussion. Jpn. J. Antibiot., 47: 951-966 (1994).
4. Agarwal, S., Pal, D. and Mitra, A. K.: Both P-gp and MRP2 mediate transport of Lopinavir, a protease inhibitor. Int. J. Pharm., 339: 139-147 (2007).
5. Booth, C. L., Brouwer, K. R. and Brouwer, K. L.: Effect of mul-tidrug resistance modulators on the hepatobiliary disposition of doxorubicin in the isolated perfused rat liver. Cancer Res., 58: 3641-3648 (1998).
6. Namkoong, E. M., Kim, I. W., Kim, D. D., Chung, S. J. and Shim, C. K.: Effect of probenecid on the biliary excretion of be-lotecan. Arch. Pharm. Res., 30: 1482-1488 (2007).
7. Su, Y., Hu, P., Lee, S. H. and Sinko, P. J.: Using novobiocin as a specific inhibitor of breast cancer resistant protein to assess the role of transporter in the absorption and disposition of topote-can. J. Pharm. Pharm. Sci., 10: 519-536 (2007).
8. Piao, Y. J., Li, X. and Choi, J. S.: Effects of verapamil on etopo-side pharmacokinetics after intravenous and oral administration in rats. Eur. J. Drug Metab. Pharmacokinet., 33: 159-164 (2008).
9. Albermann, N., Schmitz-Winnenthal, F. H., Z'graggen, K., Volk, C., Hoffmann, M. M., Haefeli, W. E. and Weiss, J.: Expression of the drug transporters MDR1/ABCB1, MRP1/ABCC1, MRP2/ ABCC2, BCRP/ABCG2, and PXR in peripheral blood mononuclear cells and their relationship with the expression in intestine and liver. Biochem. Pharmacol., 70: 949-958 (2005).
10. Jigorel, E., Le Vee, M., Boursier-Neyret, C., Parmentier, Y. and Fardel, O.: Differential regulation of sinusoidal and canalicular hepatic drug transporter expression by xenobiotics activating drug-sensing receptors in primary human hepatocytes. Drug Metab. Dispos., 34: 1756-1763 (2006).
11. Alrefai, W. A. and Gill, R. K.: Bile acid transporters: structure, function, regulation and pathophysiological implications. Pharm' Res., 24: 1803-1823 (2007).
12. Kullak-Ublick, G. A., Baretton, G. B., Oswald, M., Renner, E. L., Paumgartner, G. and Beuers, U.: Expression of the hepatocyte canalicular multidrug resistance protein (MRP2) in primary biliary cirrhosis. Hepatol. Res., 23: 78-82 (2002).
13. Umehara, K. I., Iwatsubo, T., Noguchi, K. and Kamimura, H.: Functional involvement of organic cation transporter1 (OCT1/ Oct1) in the hepatic uptake of organic cations in humans and rats. Xenobiotica., 37: 818-831 (2007).
14. Shibayama, Y., Ushinohama, K., Ikeda, R., Yoshikawa, Y., Motoya, T., Takeda, Y. and Yamada, K.: Effect of methotrexate treatment on expression levels of multidrug resistance protein 2, breast cancer resistance protein and organic anion transporters Oat1, Oat2 and Oat3 in rats. Cancer Sci., 97: 1260-1266 (2006).
15. Zamek-Gliszczynski, M. J., Hoffmaster, K. A., Tian, X., Zhao, R., Polli, J. W., Humphreys, J. E., Webster, L. O., Bridges, A. S., Kalvass, J. C. and Brouwer, K. L.: Multiple mechanisms are involved in the biliary excretion of acetaminophen sulfate in the rat: role of Mrp2 and Bcrp1. Drug Metab. Dispos., 33: 1158-1165 (2005).
16. Liu, K. X., Kato, Y., Yamazaki, M., Higuchi, O., Nakamura, T. and Sugiyama, Y.: Decrease in the hepatic clearance of hepato-cyte growth factor in carbon tetrachloride-intoxicated rats. Hepatology., 17: 651-660 (1993).
17. Sasaki, M., Suzuki, H., Ito, K., Abe, T. and Sugiyama, Y.: Tran-scellular transport of organic anions across a double-transfected Madin-Darby canine kidney II cell monolayer expressing both human organic anion-transporting polypeptide (OATP2/ SLC21A6) and Multidrug resistance-associated protein 2 (MRP2/ABCC2). J. Biol. Chem., 277: 6497-6503 (2002).
18. Pedersen, J. M., Matsson, P., Bergstroäm, C. A., Norinder, U., Hoogstraate, J. and Artursson, P.: Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2). J. Med. Chem., 51: 3275-3287 (2008).
19. Shitara, Y., Sato, H. and Sugiyama, Y.: Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs. Annu. Rev. Pharmacol. Toxicol., 45: 689-723 (2005).
20. Oswald, S., Westrup, S., Grube, M., Kroemer, H. K., Weitschies, W. and Siegmund, W.: Disposition and sterol-lowering effect of ezetimibe in multidrug resistance-associated protein 2-deficient rats. J. Pharmacol. Exp. Ther., 318: 1293-1299 (2006).
21. Machida, I., Wakusawa, S., Sanae, F., Hayashi, H., Kusakabe, A., Ninomiya, H., Yano, M. and Yoshioka, K.: Mutational analysis of the MRP2 gene and long-term follow-up of Dubin-Johnson syndrome in Japan. J. Gastroenterol., 40: 366-370 (2005).
22. Takada, T., Suzuki, H. and Sugiyama, Y.: Characterization of polarized expression of point- or deletion-mutated human BCRP/ABCG2 in LLC-PK1 cells. Pharm. Res., 22: 458-464 (2005).
23. Zaher, H., Khan, A. A., Palandra, J., Brayman, T. G., Yu, L. and Ware, J. A.: Breast cancer resistance protein (Bcrp/abcg2) is a major determinant of sulfasalazine absorption and elimination in the mouse. Mol. Pharm., 3: 55-61 (2006).
24. Kato, Y., Takahara, S., Kato, S., Kubo, Y., Sai, Y., Tamai, I., Ya-buuchi, H. and Tsuji, A.: Involvement of multidrug resistance-associated protein 2 (Abcc2) in molecular weight-dependent biliary excretion of beta-lactam antibiotics. Drug Metab. Dispos., 36: 1088-1096 (2008).
25. Ito, K., Koresawa, T., Nakano, K. and Horie, T.: Mrp2 is involved in benzylpenicillin-induced choleresis. Am. J. Physiol. Gas-trointest. Liver Physiol., 287: G42-G49 (2004).
26. Meiji Seika Kaisha, Ltd. (Japan): "Clinical investigators manuals of cefditoren pivoxil", 8-9 (2003).
27. Prime-Chapman, H., Moore, V. and Hirst, B. H.: Antibiotic exposure does not influence MRP2 functional expression in Caco-2 cells. J. Drug Target., 13: 1-6 (2005).
28. Hinoshita, E., Uchiumi, T., Taguchi, K., Kinukawa, N., Tsuneyoshi, M., Maehara, Y., Sugimachi, K. and Kuwano, M.: Increased expression of an ATP-binding cassette superfamily transporter, multidrug resistance protein 2, in human colorectal carcinomas. Clin. Cancer Res., 6: 2401-2407 (2000).
29. Smeets, P. H., van Aubel, R. A., Wouterse, A. C., van den Heuvel, J. J. and Russel, F. G.: Contribution of multidrug resistance protein 2 (MRP2/ABCC2) to the renal excretion of p-aminohip-purate (PAH) and identification of MRP4 (ABCC4) as a novel PAH transporter. J. Am. Soc. Nephrol., 15: 2828-2835 (2004).
30. Willson, T. M., Jones, S. A., Moore, J. T. and Kliewer, S. A.: Chemical genomics: functional analysis of orphan nuclear receptors in the regulation of bile acid metabolism. Med. Res. Rev., 21: 513-522 (2001).
31. Kusuhara, H. and Sugiyama, Y.: In vitro-in vivo extrapolation of transporter-mediated clearance in the liver and kidney. Drug Metab. Pharmacokinet., 24(1): 37-52 (2009).
32. Shitara, Y., Horie, T. and Sugiyama, Y.: Transporters as a determinant of drug clearance and tissue distribution. Eur. J. Pharm. Sci., 27(5): 425-446 (2006).
33. Yamazaki, M., Akiyama, S., Nishigaki, R. and Sugiyama, Y.: Uptake is the rate-limiting step in the overall hepatic elimination of pravastatin at steady-state in rats. Pharm. Res., 13(10): 1559-1564 (1996).